FDA OK's higher dose of Starpharma's VivaGel

By Melissa Trudinger
Tuesday, 03 August, 2004

Starpharma (ASX: SPL) will move to the next stage of the Phase I clinical trial for its nanodendrimer-based vaginal microbicide VivaGel, after the US FDA approved a dose increase based on the interim trial results.

After no serious adverse events were noted in patients receiving doses of the gel containing 0.5 or 1.0 per cent of the active ingredient, the company has been given the go ahead to increase the dose to 3.0 per cent.

The study is being conducted in Adelaide by CMAX, a division of the Institute for Drug Technology (IDT).

Related News

Preventing neural graft rejection in Parkinson's patients

Researchers have engineered a way to fool the immune system into accepting neural grafts as part...

Retinal health linked to dementia risk, study shows

Researchers have discovered that the blood vessels at the back of the eye — called retinal...

Pancreatic cancer hijacks metabolism switch to help it spread

Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd